Scinai Immunotherapeutics (SCNI) Stock Price, News & Analysis

Company Overview

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Key Stats

• Today's Range: $2.84 to $2.84
• 50-Day Range: $2.75 to $4.53
• 52-Week Range: $2.23 to $8.92
• Volume: 201 shs
• Average Volume: 303,447 shs
• Market Capitalization: $1.65 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Scinai Immunotherapeutics Stock Analysis - MarketRank™

Scinai Immunotherapeutics scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Scinai Immunotherapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Scinai Immunotherapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Scinai Immunotherapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.31% of the outstanding shares of Scinai Immunotherapeutics have been sold short.

Short Interest Ratio / Days to Cover

Scinai Immunotherapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Scinai Immunotherapeutics has recently decreased by 84.75%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Scinai Immunotherapeutics does not currently pay a dividend.

Dividend Growth

Scinai Immunotherapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.31% of the outstanding shares of Scinai Immunotherapeutics have been sold short.

Short Interest Ratio / Days to Cover

Scinai Immunotherapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Scinai Immunotherapeutics has recently decreased by 84.75%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for SCNI on MarketBeat in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Scinai Immunotherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

60.90% of the stock of Scinai Immunotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

58.41% of the stock of Scinai Immunotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SCNI Stock Analysis - Frequently Asked Questions

How have SCNI shares performed this year?

Scinai Immunotherapeutics' stock was trading at $5.9540 at the start of the year. Since then, SCNI stock has decreased by 50.8% and is now trading at $2.93.
View the best growth stocks for 2024 here.

When did Scinai Immunotherapeutics' stock split?

Scinai Immunotherapeutics shares reverse split on Tuesday, May 21st 2024. The 1-10 reverse split was announced on Tuesday, May 21st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 21st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Scinai Immunotherapeutics?

Shares of SCNI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Scinai Immunotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Scinai Immunotherapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET), AppLovin (APP), e.l.f. Beauty (ELF) and Disc Medicine (IRON).

Company Calendar

• Today: 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:SCNI
• Previous Symbol: NASDAQ:SCNI
• CUSIP: N/A
• CIK: 1611747
• Web: www.scinai.com
• Phone: 972-8-930-2529
• Fax: 972-8930-2531
• Employees: 31
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($254.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-6,500,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -107.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.19
• Quick Ratio: 2.73

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($9.84) per share
• Price / Book: -0.30

Miscellaneous

• Outstanding Shares: 580,000
• Free Float: 546,000
• Market Cap: $1.70 million
• Optionable: Not Optionable
• Beta: 2.46